Why do investors own the iShares S&P Global Healthcare ETF?
The iShares IXJ ETF provides investors with a targeted exposure to over 100 global healthcare companies. This includes companies in the pharmaceutical, biotechnology, and medical device space.
According to our most recent data, the IXJ ETF had $719.09 million of money invested. With IXJ’s total funds under management (FUM) figure over $100 million, the ETF meets our team’s minimum investment criteria for FUM levels. As a general rule, our team draws the line at $100 million for ETFs in the International shares sector because we believe that, relative to smaller ETFs, achieving this amount of FUM lowers the chance that the ETF issuer will close the ETF.
Fees to consider
According to our numbers, the annual management fee on the IXJ ETF is 0.47%. The issuer, iShares, collects this fee automatically.
Meaning, if you invested $2,000 in the IXJ ETF for a full year you could expect to pay management fees of around $9.40. This fee is different from the fee you pay to your brokerage provider (e.g. CommSec, NabTrade, SelfWealth, etc.), which is the fee to buy or sell the ETF. In addition to a management fee charged by the issuer, be mindful to check the ‘spread‘ for the ETF.
A fee comparison
Fees aren’t the only key consideration for ETF investors, but it’s an easy thing to do. To understand if the ETF you’re looking at is too costly, compare it with other ETFs from the same sector, and against the industry average. For example, the average management fee (MER) across all of the ETFs covered by the Best ETFs Australia team was 0.51%, which is $10.20 per $2,000 invested. Keep in mind that small changes in the fees paid can make a big difference after 10 or 20 years. You should read the IXJ Product Disclosure Statement (PDS), available on the ETF issuer’s website, because it will detail the fees, tax implications and the latest information.
Don’t stop here, to get our full IXJ ETF review, click through to this ETF review page now.
Vanguard Australian Corporate Fixed Interest Index ETF
The Vanguard VACF ETF provides exposure to corporate bonds issued by Australia’s largest banks, financial institutions, and property trusts.
With our numbers for July 2020, VACF’s FUM stood at $346.59 million. Since the VACF’s FUM is over $100 million, our investing team would say the ETF has met our minimum criteria for the total amount invested, otherwise known as FUM. A very sustainable ETF in the Index sector should be able to scale well and become profitable for the ETF issuer.
Are the fees for the VACF ETF bad?
Vanguard, the ETF issuer, charges a yearly management fee of 0.26% for the VACF ETF. Meaning, if you invested $2,000 for a full 12-month period you could expect to pay a base management fee of around $5.20.
The management fee is above the average for all ETFs on our list of ASX ETFs, but keep in mind the ETF may be able to justify the higher price tag with superior performance over time.
To discover more facts about the IXJ ETF, read our free ETF investment report.
Investing: Don't leave it to chance. Get expert help.
Don't leave your investments to chance. The expert analysts at Rask Australia have just issued a fresh copy of their popular investment report "3 cloud stocks for the revolution" and it's easy to see why hundreds of Australians have already accessed the FREE report -- this month!
You can grab your free access to the analysts' report by creating a free Rask Australia account. Absolutely no credit card or payment details necessary!
Disclaimer: Any information contained in this article is limited to general financial advice/information only. The information should not be relied upon because it has not taken into account your specific needs, goals or objectives. Please, consult a licenced and trusted financial adviser before acting on the information. Past performance is no guarantee of future performance. Nothing in this article should be considered a guarantee. Investing is risky and can result in capital loss. By reading this website, you acknowledge this warning and agree to our terms & conditions available here. This article is authorised by Owen Raszkiewicz of The Rask Group Pty Ltd.